Brought to you by 
Exscientia inks strategic drug discovery collaboration with GSK
18 Jun 2020
Executive Summary
Exscientia Ltd. entered into a drug discovery collaboration with GlaxoSmithKline PLC in which it agreed to apply its AI platform to discover novel selective small molecules with GSK for up to 10 disease-related targets.
Deal Industry
- Digital Health
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com